Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases Journal Article

   


Authors: Guo, R.; Schreyer, M.; Chang, J. C.; Rothenberg, S. M.; Henry, D.; Cotzia, P.; Kris, M. G.; Rekhtman, N.; Young, R. J.; Hyman, D. M.; Drilon, A.
Article Title: Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases
Keywords: adult; clinical article; treatment response; unclassified drug; frameshift mutation; fatigue; case report; treatment duration; bone metastasis; cancer radiotherapy; neuroimaging; nuclear magnetic resonance imaging; positron emission tomography; antineoplastic agent; computer assisted tomography; protein; drug resistance; protein p53; carcinogenesis; lung adenocarcinoma; gene fusion; brain metastasis; stereotactic radiosurgery; protein ret; lymphadenopathy; sacrum; meningeal metastasis; rib; multiplex polymerase chain reaction; next generation sequencing; human; female; priority journal; article; bronchus biopsy; homeobox protein nkx 2.1; agerafenib; eml4 protein; loxo 292
Journal Title: JCO Precision Oncology
Volume: 3
ISSN: 2473-4284
Publisher: American Society of Clinical Oncology  
Date Published: 2019-06-03
Language: English
DOI: 10.1200/PO.19.00021
PROVIDER: scopus
PMCID: PMC6724540
PUBMED: 31485557
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077482329&doi=10.1200%2fPO.19.00021&partnerID=40&md5=fcd9fe6e01f1c1ce8d06f9d2e84bfe26
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Natasha Rekhtman
    424 Rekhtman
  2. Robert J Young
    228 Young
  3. David Hyman
    354 Hyman
  4. Mark Kris
    869 Kris
  5. Alexander Edward Drilon
    632 Drilon
  6. Jason Chih-Peng Chang
    133 Chang
  7. Mark W Schreyer
    5 Schreyer
  8. Robin Guo
    24 Guo
Related MSK Work